Two high profile COVID-19 papers retracted
The Lancet and The New England Journal of Medicine (NEJM) have retracted two separate studies that relied on de-identified electronic health records from a company called Surgisphere. The Lancet study raised safety concerns about the malaria drug hydroxychloroquine as a COVID-19 treatment, which prompted some regulators to temporarily pause trials of the drug. The NEJM study found no evidence that blood-pressure medications were harmful for people with COVID-19 and underlying cardiovascular disease. The authors requested that the papers be retracted after questions were raised about the underlying data, and Surgisphere refused to provide them for legal and confidentiality reasons.
A third study using Surgisphere data, uploaded to and then removed from social-sciences preprint server SSRN, has contributed to enthusiasm for the antiparasitic drug ivermectin in South America. “Who retracts this ivermectin ghost in Latin America?” asks global-health researcher Carlos Chaccour. “There’s no high-profile journal saying this was wrong.”
Nature | 7 min readReference: retracted Lancet paper & retracted New England Journal of Medicine paper
A third study using Surgisphere data, uploaded to and then removed from social-sciences preprint server SSRN, has contributed to enthusiasm for the antiparasitic drug ivermectin in South America. “Who retracts this ivermectin ghost in Latin America?” asks global-health researcher Carlos Chaccour. “There’s no high-profile journal saying this was wrong.”
No hay comentarios:
Publicar un comentario